The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of single doses and multiple doses of an investigation drug that is being developed to treat sickle cell disease, in healthy participants.
During Study 2037, participants will receive the investigative treatment via three subcutaneous injections.
There is one screening appointment and a COVID test before the first overnight stay. There are three outpatient visits. Compensation for study participation may be provided for time and travel of $6,025.
This study has been approved by an independent ethics committee.
Call Andy at 651-332-1810 or email her at andyh@nucleusnetwork.com to discuss your eligibility today!